167 related articles for article (PubMed ID: 11536289)
21. Reversibility of scrapie inactivation is enhanced by copper.
McKenzie D; Bartz J; Mirwald J; Olander D; Marsh R; Aiken J
J Biol Chem; 1998 Oct; 273(40):25545-7. PubMed ID: 9748215
[TBL] [Abstract][Full Text] [Related]
22. Disulfide-crosslink scanning reveals prion-induced conformational changes and prion strain-specific structures of the pathological prion protein PrP
Taguchi Y; Lu L; Marrero-Winkens C; Otaki H; Nishida N; Schatzl HM
J Biol Chem; 2018 Aug; 293(33):12730-12740. PubMed ID: 29934306
[TBL] [Abstract][Full Text] [Related]
23. Sialylation of prion protein controls the rate of prion amplification, the cross-species barrier, the ratio of PrPSc glycoform and prion infectivity.
Katorcha E; Makarava N; Savtchenko R; D'Azzo A; Baskakov IV
PLoS Pathog; 2014 Sep; 10(9):e1004366. PubMed ID: 25211026
[TBL] [Abstract][Full Text] [Related]
24. The H187R mutation of the human prion protein induces conversion of recombinant prion protein to the PrP(Sc)-like form.
Hosszu LL; Tattum MH; Jones S; Trevitt CR; Wells MA; Waltho JP; Collinge J; Jackson GS; Clarke AR
Biochemistry; 2010 Oct; 49(40):8729-38. PubMed ID: 20718410
[TBL] [Abstract][Full Text] [Related]
25. Prions.
Colby DW; Prusiner SB
Cold Spring Harb Perspect Biol; 2011 Jan; 3(1):a006833. PubMed ID: 21421910
[TBL] [Abstract][Full Text] [Related]
26. Genetic and infectious prion diseases.
Prusiner SB
Arch Neurol; 1993 Nov; 50(11):1129-53. PubMed ID: 8105771
[TBL] [Abstract][Full Text] [Related]
27. [Molecular pathogenesis of spongiform encephalopathy].
Aguzzi A; Maddalena A; Brandner S; Klein M
Pathologica; 1997 Oct; 89(5):481-90. PubMed ID: 9489393
[No Abstract] [Full Text] [Related]
28. Prions: protein only or something more? Overview of potential prion cofactors.
Fasano C; Campana V; Zurzolo C
J Mol Neurosci; 2006; 29(3):195-214. PubMed ID: 17085779
[TBL] [Abstract][Full Text] [Related]
29. The emerging principles of mammalian prion propagation and transmissibility barriers: Insight from studies in vitro.
Surewicz WK; Jones EM; Apetri AC
Acc Chem Res; 2006 Sep; 39(9):654-62. PubMed ID: 16981682
[TBL] [Abstract][Full Text] [Related]
30. A new method for the characterization of strain-specific conformational stability of protease-sensitive and protease-resistant PrPSc.
Pirisinu L; Di Bari M; Marcon S; Vaccari G; D'Agostino C; Fazzi P; Esposito E; Galeno R; Langeveld J; Agrimi U; Nonno R
PLoS One; 2010 Sep; 5(9):e12723. PubMed ID: 20856860
[TBL] [Abstract][Full Text] [Related]
31. Molecular architecture of human prion protein amyloid: a parallel, in-register beta-structure.
Cobb NJ; Sönnichsen FD; McHaourab H; Surewicz WK
Proc Natl Acad Sci U S A; 2007 Nov; 104(48):18946-51. PubMed ID: 18025469
[TBL] [Abstract][Full Text] [Related]
32. Prions: a model of conformational disease?
Morinet F
Pathol Biol (Paris); 2014 Apr; 62(2):96-9. PubMed ID: 24656441
[TBL] [Abstract][Full Text] [Related]
33. Prion protein functions and dysfunction in prion diseases.
Sakudo A; Ikuta K
Curr Med Chem; 2009; 16(3):380-9. PubMed ID: 19149584
[TBL] [Abstract][Full Text] [Related]
34. Prion diseases and the central dogma of molecular biology.
Hunter N
Trends Microbiol; 1999 Jul; 7(7):265-6. PubMed ID: 10390630
[No Abstract] [Full Text] [Related]
35. Insights into Mechanisms of Transmission and Pathogenesis from Transgenic Mouse Models of Prion Diseases.
Moreno JA; Telling GC
Methods Mol Biol; 2017; 1658():219-252. PubMed ID: 28861793
[TBL] [Abstract][Full Text] [Related]
36. Prion protein and its conformational conversion: a structural perspective.
Surewicz WK; Apostol MI
Top Curr Chem; 2011; 305():135-67. PubMed ID: 21630136
[TBL] [Abstract][Full Text] [Related]
37. Using isotopically-coded hydrogen peroxide as a surface modification reagent for the structural characterization of prion protein aggregates.
Serpa JJ; Makepeace KA; Borchers TH; Wishart DS; Petrotchenko EV; Borchers CH
J Proteomics; 2014 Apr; 100():160-6. PubMed ID: 24316355
[TBL] [Abstract][Full Text] [Related]
38. Immobilized prion protein undergoes spontaneous rearrangement to a conformation having features in common with the infectious form.
Leclerc E; Peretz D; Ball H; Sakurai H; Legname G; Serban A; Prusiner SB; Burton DR; Williamson RA
EMBO J; 2001 Apr; 20(7):1547-54. PubMed ID: 11285219
[TBL] [Abstract][Full Text] [Related]
39. Recombinant prion protein refolded with lipid and RNA has the biochemical hallmarks of a prion but lacks in vivo infectivity.
Timmes AG; Moore RA; Fischer ER; Priola SA
PLoS One; 2013; 8(7):e71081. PubMed ID: 23936256
[TBL] [Abstract][Full Text] [Related]
40. Aptamers against prion proteins and prions.
Gilch S; Schätzl HM
Cell Mol Life Sci; 2009 Aug; 66(15):2445-55. PubMed ID: 19396399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
